Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary…
- C. Aghajanian, S. Blank, +6 authors L. Nycum
- Journal of clinical oncology : official journal…
- 20 June 2011
PURPOSE This randomized, multicenter, blinded, placebo-controlled phase III trial tested the efficacy and safety of bevacizumab (BV) with gemcitabine and carboplatin (GC) compared with GC in… Expand
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
- R. Salani, F. Backes, +4 authors B. Goff
- American journal of obstetrics and gynecology
- 1 June 2011
Although gynecologic cancers account for only 10% of all new cancer cases in women, these cancers account for 20% of all female cancer survivors. Improvements in cancer care have resulted in almost… Expand
A Psychoeducational Intervention for Sexual Dysfunction in Women with Gynecologic Cancer
- L. Brotto, J. Heiman, +5 authors A. Blaricom
- Psychology, Medicine
- Archives of sexual behavior
- 1 April 2008
Treatment of early-stage cervical and endometrial cancer has been associated with significant sexual difficulties in at least half of women following hysterectomy. Despite the fact that women report… Expand
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.
CONTEXT Women with ovarian cancer frequently report symptoms prior to diagnosis, but distinguishing these symptoms from those that normally occur in women remains problematic. OBJECTIVE To compare… Expand
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
- C. Aghajanian, B. Goff, L. Nycum, Y. Wang, A. Husain, S. Blank
- Gynecologic oncology
- 1 October 2015
OBJECTIVE OCEANS is a randomized, placebo (PL)-controlled, phase 3 trial evaluating the efficacy and safety of bevacizumab combined with gemcitabine+carboplatin (GC) for patients with… Expand
Ovarian carcinoma diagnosis
Ovarian carcinoma often is called the “silent killer” because the disease usually is not detected until an advanced stage. The authors' goal was to evaluate preoperative symptoms and factors that may… Expand
Uterine papillary serous carcinoma: patterns of metastatic spread.
Uterine papillary serous carcinoma (UPSC) is a distinct histologic type of endometrial cancer which is associated with a high relapse rate and poor prognosis. Between 1983 and 1993, 50 patients with… Expand
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
Between 1982 and 1992, 24 women with Stage III clear cell ovarian cancer were identified from the tumor registry. Thirty-four women with Stage III papillary serous tumors treated between 1987 and… Expand
Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
This study was undertaken to examine the incidence and conditions under which lymph node metastases are present and patterns of recurrence in women with uterine leiomyosarcoma (LMS) and endometrial… Expand
Development of an ovarian cancer symptom index: possibilities for earlier detection.
BACKGROUND Currently, screening for ovarian cancer is not recommended for the general population. Targeting women with specific symptoms for screening has been evaluated only recently, because it was… Expand